Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Author index

Page Path
HOME > Browse articles > Author index
Search
Myong Hoon Ihn 4 Articles
Curative Resection for Metachronous Pulmonary Metastases from Colorectal Cancer: Analysis of Survival Rates and Prognostic Factors
Myong Hoon Ihn, Duck-Woo Kim, Sukki Cho, Heung-Kwon Oh, Sanghoon Jheon, Kwhanmien Kim, Eun Shin, Hye Seung Lee, Jin-Haeng Chung, Sung-Bum Kang
Cancer Res Treat. 2017;49(1):104-115.   Published online May 9, 2016
DOI: https://doi.org/10.4143/crt.2015.367
AbstractAbstract PDFPubReaderePub
Purpose
Prognostic factors in patients with pulmonary metastases (PM) from colorectal cancer (CRC) are still controversial. This study assessed oncologic outcomes and prognostic factors in patients with metachronous PM from CRC.
Materials and Methods
Between June 2003 and December 2011, 122 patients with CRC underwent curative resection of PM detected at least 4 months after CRC resection. Clinico-pathological factors selected from the prospectively maintained database were analyzed retrospectively.
Results
The median disease-free interval (DFI) between resection of the primary tumor and detection of PM was 22.0 months (range, 4 to 85 months). Solitary PM were detected in 77 patients (63.1%), with a median maximal tumor diameter of 12.0 mm (range, 2 to 70 mm). Of 52 patients who underwent mediastinal lymph node (LN) dissection, eight patients had LN involvement. Five-year overall survival and disease-free survival (DFS) rates after initial pulmonary metastasectomy were 66.4% and 50.9%, respectively. DFI, mediastinal LN involvement, and the number and distribution of PM were significantly prognostic factors for DFS. In multivariable analysis DFI ≥ 12 months, solitary lesion, and absence of mediastinal LN involvement were independently prognostic for DFS. Of the 122 patients, 48 patients (39.3%) developed recurrent PM a median 13.0 months after initial pulmonary metastasectomy. Recurrent DFI was independently prognostic of DFS in patients who underwent repeated pulmonary metastasectomy.
Conclusion
There is a potential survival benefit for patients with metachronous PM from CRC who undergo pulmonary metastasectomy, even those with recurrent PM. Pulmonary metastasectomy should be considered in selected patients, particularly those with longer DFI, solitary lesions, and absence of mediastinal LN involvement.

Citations

Citations to this article as recorded by  
  • circEIF3I Promotes Colorectal Cancer Metastasis by Regulating the miR‐328‐3p/NCAPH Axis
    Yali Zhao, Yan He, Zhiyuan Xiao, Le Xin, Mingjing Deng, Mingxia Yao, Guan Huang
    Molecular Carcinogenesis.2025; 64(3): 450.     CrossRef
  • Role of Pulmonary Metastasectomy in Colorectal Cancer
    Zamaan Hooda, Michael Eisenberg, Mara B. Antonoff
    Thoracic Surgery Clinics.2025; 35(2): 143.     CrossRef
  • Outcomes and prognostic factors of repeat pulmonary metastasectomy
    Ryu Kanzaki, Hirokazu Watari, Akiisa Omura, Sachi Kawagishi, Ryo Tanaka, Tomohiro Maniwa, Jiro Okami
    Interdisciplinary CardioVascular and Thoracic Surgery.2024;[Epub]     CrossRef
  • Development of a protocol for whole-lung in vivo lung perfusion-assisted photodynamic therapy using a porcine model
    Khaled Ramadan, Tina Saeidi, Edson Brambate, Vanderlei Bagnato, Marcelo Cypel, Lothar Lilge
    Journal of Biomedical Optics.2024;[Epub]     CrossRef
  • Preoperative prognostic factors for 5-year survival following pulmonary metastasectomy from colorectal cancer: a systematic review and meta-analysis
    Andreas Gkikas, Christos Kakos, Savvas Lampridis, Peter J Godolphin, Davide Patrini
    European Journal of Cardio-Thoracic Surgery.2023;[Epub]     CrossRef
  • FUT2 inhibits the EMT and metastasis of colorectal cancer by increasing LRP1 fucosylation
    Lingnan He, Zijun Guo, Weijun Wang, Shuxin Tian, Rong Lin
    Cell Communication and Signaling.2023;[Epub]     CrossRef
  • PET/MRI in colorectal and anal cancers: an update
    Vetri Sudar Jayaprakasam, Semra Ince, Garima Suman, Pankaj Nepal, Thomas A. Hope, Raj Mohan Paspulati, Tyler J. Fraum
    Abdominal Radiology.2023; 48(12): 3558.     CrossRef
  • A review of surgery for lung metastasis from colorectal cancer
    Yu-Kwang Lee, Mong-Wei Lin, Ke-Cheng Chen, Pei-Ming Huang, Shuenn-Wen Kuo, Jang-Ming Lee
    Formosan Journal of Surgery.2023;[Epub]     CrossRef
  • Long-term outcomes and early recurrence after resection for metachronous pulmonary metastases from colorectal cancer
    Shintaro Hashimoto, Tetsuro Tominaga, Takashi Nonaka, Keisuke Noda, Soishiro Kiya, Toshio Shiraishi, Kaido Oishi, Yuma Takamura, Shoto Yamazaki, Masato Araki, Yorihisa Sumida, Takuro Miyazaki, Ryotaro Kamohara, Shigeyuki Morino, Keitaro Matsumoto, Akihiro
    Langenbeck's Archives of Surgery.2023;[Epub]     CrossRef
  • Survival and prognostic factors of isolated pulmonary metastases originating from colorectal cancer: An 8-year single-center experience
    Ameera S. Balhareth, Abdullah S. AlQattan, Hassan M. Alshaqaq, Abdullah M. Alkhalifa, Alaa A. Al Abdrabalnabi, Muna S. Alnamlah, Deborah MacNamara
    Annals of Medicine and Surgery.2022; 77: 103559.     CrossRef
  • Long term survival after multiple microwave ablations for colorectal cancer lung metastases: A case report
    Victoria T. Y Lee, Yueh-Hsin Lin, Derek Glenn, Suhrid Lodh, David L. Morris
    Radiology Case Reports.2022; 17(6): 2038.     CrossRef
  • A model to assess acute and delayed lung toxicity of oxaliplatin during in vivo lung perfusion
    Khaled Ramadan, Bruno Gomes, Mauricio Pipkin, Mariola Olkowicz, Barbara Bojko, Arnaud Romeo Mbadjeu Hondjeu, Shaf Keshavjee, Thomas Waddell, Janusz Pawliszyn, Marcelo Cypel
    The Journal of Thoracic and Cardiovascular Surgery.2021; 161(5): 1626.     CrossRef
  • Prognostic value of KRAS mutation in patients undergoing pulmonary metastasectomy for colorectal cancer: A systematic review and meta-analysis
    Junfeng Huang, Qing Zang, Yaokai Wen, Zhe Pan, Zhiyuan Yao, Mingkai Huang, Jiongqiang Huang, Jingsong Chen, Rongchang Wang
    Critical Reviews in Oncology/Hematology.2021; 160: 103308.     CrossRef
  • Systematic Review of Treatments for Colorectal Metastases in Elderly Patients to Guide Surveillance Cessation Following Hepatic Resection for Colorectal Liver Metastases
    Edward Alabraba, Dhanny Gomez
    American Journal of Clinical Oncology.2021; 44(5): 210.     CrossRef
  • Determination of Optical Properties and Photodynamic Threshold of Lung Tissue for Treatment Planning of In Vivo Lung Perfusion Assisted Photodynamic Therapy
    Khaled T. Ramadan, Christopher McFadden, Bruno Gomes, Fynn Schwiegelshohn, Rafaela V.P. Ribeiro, Harley H.L. Chan, Vaughn Betz, Marcelo Cypel, Lothar Lilge
    Photodiagnosis and Photodynamic Therapy.2021; 35: 102353.     CrossRef
  • Survival outcome of pulmonary metastasectomy among the patients with colorectal cancers
    Oya Yıldız, Shute Ailia Dae, Alper Fındıkcıoglu, Fatih Kose
    Revista da Associação Médica Brasileira.2021; 67(7): 1015.     CrossRef
  • Circular RNA circHERC4 as a novel oncogenic driver to promote tumor metastasis via the miR-556-5p/CTBP2/E-cadherin axis in colorectal cancer
    Jiehua He, Ziqiang Chu, Wei Lai, Qiusheng Lan, Yujie Zeng, Daning Lu, Shaowen Jin, Heyang Xu, Pengwei Su, Dong Yin, Zhonghua Chu, Lu Liu
    Journal of Hematology & Oncology.2021;[Epub]     CrossRef
  • Vaccines for colorectal cancer: an update
    Mostafa Sarvizadeh, Faezeh Ghasemi, Fatemeh Tavakoli, Sara Sadat Khatami, Ebrahim Razi, Hossein Sharifi, Nousin Moussavi Biouki, Mohsen Taghizadeh
    Journal of Cellular Biochemistry.2019; 120(6): 8815.     CrossRef
  • Surgical management of colorectal lung metastases
    Joseph D. Phillips, Rian M. Hasson
    Journal of Surgical Oncology.2019; 119(5): 629.     CrossRef
  • Chemotherapy for resected colorectal cancer pulmonary metastases: Utilization and outcomes in routine clinical practice
    S. Karim, S. Nanji, K. Brennan, C.S. Pramesh, C.M. Booth
    European Journal of Surgical Oncology (EJSO).2017; 43(8): 1481.     CrossRef
  • The characteristics and outcomes of small bowel adenocarcinoma: a multicentre retrospective observational study
    Hiroyuki Sakae, Hiromitsu Kanzaki, Junichiro Nasu, Yutaka Akimoto, Kazuhiro Matsueda, Masao Yoshioka, Masahiro Nakagawa, Shinichiro Hori, Masafumi Inoue, Tomoki Inaba, Atsushi Imagawa, Masahiro Takatani, Ryuta Takenaka, Seiyu Suzuki, Toshiyoshi Fujiwara,
    British Journal of Cancer.2017; 117(11): 1607.     CrossRef
  • 10,944 View
  • 201 Download
  • 27 Web of Science
  • 21 Crossref
Close layer
Prospective Study on the Incidence of Postoperative Venous Thromboembolism in Korean Patients with Colorectal Cancer
Eunyoung Lee, Sung-Bum Kang, Sang Il Choi, Eun Ju Chun, Min Jeong Kim, Duck-Woo Kim, Heung-Kwon Oh, Myong Hoon Ihn, Jin Won Kim, Soo-Mee Bang, Jeong-Ok Lee, Yu Jung Kim, Jee Hyun Kim, Jong Seok Lee, Keun-Wook Lee
Cancer Res Treat. 2016;48(3):978-989.   Published online November 17, 2015
DOI: https://doi.org/10.4143/crt.2015.311
AbstractAbstract PDFPubReaderePub
Purpose
Pharmacologic thromboprophylaxis is routinely recommended for Western cancer patients undergoing major surgery for prevention of venous thromboembolism (VTE). However, it is uncertainwhetherroutine administration of pharmacologic thromboprophylaxis is necessary in all Asian surgical cancer patients. This prospective study was conducted to examine the incidence of and risk factors for postoperative VTE in Korean colorectal cancer (CRC) patients undergoing major abdominal surgery. Materials and Methods This study comprised two cohorts, and none of patients received perioperative pharmacologic thromboprophylaxis. In cohort A (n=400), patients were routinely screened for VTE using lower-extremity Doppler ultrasonography (DUS) on postoperative days 5-14. In cohort B (n=148), routine DUS was not performed, and imaging was only performed when there were symptoms or signs that were suspicious for VTE. The primary endpoint was the VTE incidence at 4 weeks postoperatively in cohort A.
Results
The postoperative incidence of VTE was 3.0% (n=12) in cohort A. Among the 12 patients, eight had distal calf vein thromboses and one had symptomatic thrombosis. Age ≥ 70 years (odds ratio [OR], 5.61), ≥ 2 comorbidities (OR, 13.42), and white blood cell counts of > 10,000/μL (OR, 17.43) were independent risk factors for postoperative VTE (p < 0.05). In cohort B, there was one case of VTE (0.7%). Conclusion The postoperative incidence of VTE, which included asymptomatic cases, was 3.0% in Korean CRC patients who did not receive pharmacologic thromboprophylaxis. Perioperative pharmacologic thromboprophylaxis should be administered to Asian CRC patients on a riskstratified basis.

Citations

Citations to this article as recorded by  
  • The 2024 Korean Enhanced Recovery After Surgery (ERAS) guidelines for colorectal cancer: a secondary publication
    Kil-yong Lee, Soo Young Lee, Miyoung Choi, Moonjin Kim, Ji Hong Kim, Ju Myung Song, Seung Yoon Yang, In Jun Yang, Moon Suk Choi, Seung Rim Han, Eon Chul Han, Sang Hyun Hong, Do Joong Park, Sang-Jae Park
    Annals of Coloproctology.2025; 41(1): 3.     CrossRef
  • Circulating Blood Biomarkers and Risk of Venous Thromboembolism in Cancer Patients: A Systematic Review and Meta-Analysis
    Danielle Carole Roy, Tzu-Fei Wang, Ronda Lun, Amin Zahrai, Ranjeeta Mallick, Dylan Burger, Gabriele Zitikyte, Steven Hawken, Philip Wells
    Thrombosis and Haemostasis.2024; 124(12): 1117.     CrossRef
  • Venous thromboembolism among Asian populations with localized colorectal cancer undergoing curative resection: is pharmacological thromboprophylaxis required? A systematic review and meta-analysis
    Shih Jia Janice Tan, Emile Kwong-Wei Tan, Yvonne Ying Ru Ng, Rehena Sultana, John Carson Allen, Isaac Seow-En, Ronnie Mathew, Aik Yong Chok
    Annals of Coloproctology.2024; 40(3): 200.     CrossRef
  • The 2024 Korean Enhanced Recovery After Surgery guidelines for colorectal cancer
    Kil-yong Lee, Soo Young Lee, Miyoung Choi, Moonjin Kim, Ji Hong Kim, Ju Myung Song, Seung Yoon Yang, In Jun Yang, Moon Suk Choi, Seung Rim Han, Eon Chul Han, Sang Hyun Hong, Do Joong Park, Sang-Jae Park
    Annals of Clinical Nutrition and Metabolism.2024; 16(2): 22.     CrossRef
  • Low prevalence of deep vein thrombosis among colorectal cancer patients undergoing surgery in Taiwan: A prospective cross-sectional study
    Hsuan-Yu Lin, Ting-Ming Huang, Ching-Yeh Lin, Ming-Ching Shen
    Asian Journal of Surgery.2023; 46(3): 1426.     CrossRef
  • Clinical characteristics and disease course of splanchnic vein thrombosis in gastrointestinal cancers: A prospective cohort study
    Minsu Kang, Koung Jin Suh, Ji-Won Kim, Ja Min Byun, Jin Won Kim, Ji Yun Lee, Jeong-Ok Lee, Soo-Mee Bang, Yu Jung Kim, Se Hyun Kim, Jee Hyun Kim, Jong Seok Lee, Keun-Wook Lee, Pal Bela Szecsi
    PLOS ONE.2022; 17(1): e0261671.     CrossRef
  • Application of venous thromboembolism prophylaxis program in patients with colorectal cancer using the enhanced recovery after surgery protocol
    Hyung Jin Cho, In Kyu Lee, Yoon Suk Lee, Sang Seob Yun, Sun Cheol Park, Jang Yong Kim, Chul Seung Lee
    European Journal of Surgical Oncology.2022; 48(6): 1384.     CrossRef
  • Racial disparities in cancer-associated thrombosis
    Tatini Datta, Ann Brunson, Anjlee Mahajan, Theresa Keegan, Ted Wun
    Blood Advances.2022; 6(10): 3167.     CrossRef
  • Coagulation and Aging: Implications for the Anesthesiologist
    Sarina L. Tschan, Daniel Bolliger
    Current Anesthesiology Reports.2021; 11(4): 387.     CrossRef
  • Perioperative Short Term Prophylaxis against Deep Vein Thrombosis after Major Abdominal Cancer Surgery: Retrospective Cohort Study
    Nuray Colapkulu-Akgul, Ibrahim Ali Ozemir, Damla Beyazadam, Orhan Alimoglu
    Vascular Specialist International.2021;[Epub]     CrossRef
  • Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update
    Nigel S. Key, Alok A. Khorana, Nicole M. Kuderer, Kari Bohlke, Agnes Y.Y. Lee, Juan I. Arcelus, Sandra L. Wong, Edward P. Balaban, Christopher R. Flowers, Charles W. Francis, Leigh E. Gates, Ajay K. Kakkar, Mark N. Levine, Howard A. Liebman, Margaret A. T
    Journal of Clinical Oncology.2020; 38(5): 496.     CrossRef
  • Rivaroxaban for extended antithrombotic prophylaxis after laparoscopic surgery for colorectal cancer. Design of the PRO-LAPS II STUDY
    Cecilia Becattini, Ugo Pace, Fabio Rondelli, Paolo Delrio, Graziano Ceccarelli, Michela Boncompagni, Luigina Graziosi, Adriana Visonà, Damiano Chiari, Giampiero Avruscio, Stefania Frasson, Gualberto Gussoni, Alessia Biancafarina, Giuseppe Camporese, Annib
    European Journal of Internal Medicine.2020; 72: 53.     CrossRef
  • Incidence of postsurgical pulmonary embolism and deep venous thrombosis: a single-center retrospective observational study
    Hitomi Otsuka, Makoto Izumi, Eriko Ota, Noriaki Mochizuki
    JA Clinical Reports.2020;[Epub]     CrossRef
  • The impact of hereditary thrombophilia on the incidence of postoperative venous thromboembolism in colorectal cancer patients: a prospective cohort study
    Jan Ulrych, Tomas Kvasnicka, Vladimir Fryba, Martin Komarc, Ivana Malikova, Radka Brzezkova, Jan Kvasnicka Jr, Zdenek Krska, Jan Briza, Jan Kvasnicka
    European Surgery.2019; 51(1): 5.     CrossRef
  • Incidence, risk factors, and outcomes of venous thromboembolism after oncologic surgery: A systematic review and meta-analysis
    Mao Li, Qiang Guo, Weiming Hu
    Thrombosis Research.2019; 173: 48.     CrossRef
  • The prevalence of venous thromboembolism in rectal surgery: a systematic review and meta-analysis
    Joshua W. Hayes, Éanna J. Ryan, Patrick A. Boland, Ben Creavin, Michael E. Kelly, David Beddy
    International Journal of Colorectal Disease.2019; 34(5): 849.     CrossRef
  • European guidelines on perioperative venous thromboembolism prophylaxis
    Sibylle Kozek-Langenecker, Christian Fenger-Eriksen, Emmanuel Thienpont, Giedrius Barauskas
    European Journal of Anaesthesiology.2018; 35(2): 116.     CrossRef
  • The identification of risk factors for venous thromboembolism in gastrointestinal oncologic surgery
    Geoffrey Bellini, Annabelle Teng, Nisha Kotecha, Elie Sutton, Chun Kevin Yang, Michael Passeri, David Y. Lee, Keith Rose
    Journal of Surgical Research.2016; 205(2): 279.     CrossRef
  • 13,475 View
  • 184 Download
  • 18 Web of Science
  • 18 Crossref
Close layer
Clinicopathological Features and Type of Surgery for Lynch Syndrome: Changes during the Past Two Decades
Il Tae Son, Duck-Woo Kim, Seung-Yong Jeong, Young-Kyoung Shin, Myong Hoon Ihn, Heung-Kwon Oh, Sung-Bum Kang, Kyu Joo Park, Jae Hwan Oh, Ja-Lok Ku, Jae-Gahb Park
Cancer Res Treat. 2016;48(2):605-611.   Published online May 26, 2015
DOI: https://doi.org/10.4143/crt.2015.092
AbstractAbstract PDFPubReaderePub
Purpose
The Korean Hereditary Tumor Registry, the first and one of the largest registries of hereditary tumors in Korea, has registered about 500 families with hereditary cancer syndromes. This study evaluates the temporal changes in clinicopathologic features and surgical patterns of Lynch syndrome (LS) patients.
Materials and Methods
Data on 182 unrelated LS patients were collected retrospectively. The patients were divided into the period 1 group (registered in 1990-2004) and 2 (registered in 2005-2014). The clinical characteristics of the two groups were compared to identify changes over time.
Results
The period 1 group included 76 patients; the period 2 group, 106 patients. The mean ages at diagnosis were 45.1 years (range, 13 to 85 years) for group 1 and 49.7 years (range, 20 to 84 years) for group 2 (p=0.015). The TNM stage at diagnosis did not differ significantly— period 1 group: stage 0-I (n=18, 23.7%), II (n=37, 48.7%), III (n=19, 25.0%), and IV (n=2, 2.6%); period 2 group: stage 0-I (n=30, 28.3%), II (n=35, 33.0%), III (n=37, 34.9%), and IV (n=4, 3.8%). Extended resection was more frequently performed (55/76, 72.4%) in the period 1 group than period 2 (49/106, 46.2%) (p=0.001).
Conclusion
Colorectal cancer in patients with LS registered at the Korean Hereditary Tumor Registry is still diagnosed at an advanced stage, more than two decades after registry’s establishment. Segmental resection was more frequently performed in the past decade. A prompt nationwide effort to raise public awareness of hereditary colorectal cancer and to support hereditary cancer registries is required in Korea.

Citations

Citations to this article as recorded by  
  • Universal Screening for Lynch Syndrome Compared with Pedigree-Based Screening: 10-Year Experience in a Tertiary Hospital
    Min Hyun Kim, Duck-Woo Kim, Hye Seung Lee, Su Kyung Bang, Soo Hyun Seo, Kyung Un Park, Heung-Kwon Oh, Sung-Bum Kang
    Cancer Research and Treatment.2023; 55(1): 179.     CrossRef
  • Deciding the operation type according to mismatch repair status among hereditary nonpolyposis colorectal cancer patients: should a tailored approach be applied, or does one size fit all?
    Chun-Kai Liao, Yueh-Chen Lin, Yu-Jen Hsu, Yih-Jong Chern, Jeng-Fu You, Jy-Ming Chiang
    Hereditary Cancer in Clinical Practice.2021;[Epub]     CrossRef
  • Comparison of oncologic outcomes between patients with Lynch syndrome and sporadic microsatellite instability-high colorectal cancer
    Il Tae Son, Duck-Woo Kim, Min Hyun Kim, Young-Kyoung Shin, Ja-Lok Ku, Heung-Kwon Oh, Sung-Bum Kang, Seung-Yong Jeong, Kyu Joo Park
    Annals of Surgical Treatment and Research.2021; 101(1): 13.     CrossRef
  • Germline Variants in MLH1, MSH2, and MSH6 in Korean Patients with Lynch Syndrome
    Kyoung-Jin Park, Dong Kyung Chang, Hee Cheol Kim, Jong-Won Kim
    Laboratory Medicine Online.2018; 8(4): 156.     CrossRef
  • Efficacy, functional outcome and post‑operative complications of total abdominal colectomy with ileorectal anastomosis vs. segmental colectomy in hereditary non‑polyposis colorectal cancer
    Jie Sun, Mingjie Dong, Xiaoping Xiao
    Experimental and Therapeutic Medicine.2018;[Epub]     CrossRef
  • 12,317 View
  • 107 Download
  • 4 Web of Science
  • 5 Crossref
Close layer
Validation of Prediction Models for Mismatch Repair Gene Mutations in Koreans
Soo Young Lee, Duck-Woo Kim, Young-Kyoung Shin, Myong Hoon Ihn, Sung Min Lee, Heung-Kwon Oh, Ja-Lok Ku, Seung-Yong Jeong, Jae Bong Lee, Soyeon Ahn, Sungho Won, Sung-Bum Kang
Cancer Res Treat. 2016;48(2):668-675.   Published online June 5, 2015
DOI: https://doi.org/10.4143/crt.2014.288
AbstractAbstract PDFPubReaderePub
Purpose
Lynch syndrome, the commonest hereditary colorectal cancer syndrome, is caused by germline mutations in mismatch repair (MMR) genes. Three recently developed prediction models for MMR gene mutations based on family history and clinical features (MMRPredict, PREMM1,2,6, and MMRPro) have been validated only in Western countries. In this study, we propose validating these prediction models in the Korean population.
Materials and Methods
We collected MMR gene analysis data from 188 individuals in the Korean Hereditary Tumor Registry. The probability of gene mutation was calculated using three prediction models, and the overall diagnostic value of each model compared using receiver operator characteristic (ROC) curves and area under the ROC curve (AUC). Quantitative test characteristics were calculated at sensitivities of 90%, 95%, and 98%.
Results
Of the individuals analyzed, 101 satisfied Amsterdam criteria II, and 87 were suspected hereditary nonpolyposis colorectal cancer. MMR mutations were identified in 62 of the 188 subjects (33.0%). All three prediction models showed a poor predictive value of AUC (MMRPredict, 0.683; PREMM1,2,6, 0.709; MMRPro, 0.590). Within the range of acceptable sensitivity (> 90%), PREMM1,2,6 demonstrated higher specificity than the other models.
Conclusion
In the Korean population, overall predictive values of the three models (MMRPredict, PREMM1,2,6, MMRPro) for MMR gene mutations are poor, compared with their performance in Western populations. A new prediction model is therefore required for the Korean population to detect MMR mutation carriers, reflecting ethnic differences in genotype-phenotype associations.

Citations

Citations to this article as recorded by  
  • Performance evaluation of predictive models for detecting MMR gene mutations associated with Lynch syndrome in cancer patients in a Chinese cohort in Taiwan
    Fei‐Hung Hung, Hung‐Pin Peng, Chen‐Fang Hung, Ling‐Ling Hsieh, An‐Suei Yang, Yong Alison Wang
    International Journal of Cancer.2024; 155(12): 2201.     CrossRef
  • Absence of constitutional MLH1 promoter methylation in Pakistani colorectal cancer patients
    Ayesha Azeem, Humaira Naeemi, Noor Muhammad, Asif Loya, Muhammed Aasim Yusuf, Muhammad Usman Rashid
    Gene Reports.2024; 36: 101995.     CrossRef
  • Prevalence and spectrum of MLH1, MSH2, and MSH6 pathogenic germline variants in Pakistani colorectal cancer patients
    Muhammad Usman Rashid, Humaira Naeemi, Noor Muhammad, Asif Loya, Jan Lubiński, Anna Jakubowska, Muhammed Aasim Yusuf
    Hereditary Cancer in Clinical Practice.2019;[Epub]     CrossRef
  • Evaluation of current prediction models for Lynch syndrome: updating the PREMM5 model to identify PMS2 mutation carriers
    A. Goverde, M. C. W. Spaander, D. Nieboer, A. M. W. van den Ouweland, W. N. M. Dinjens, H. J. Dubbink, C. J. Tops, S. W. ten Broeke, M. J. Bruno, R. M. W. Hofstra, E. W. Steyerberg, A. Wagner
    Familial Cancer.2018; 17(3): 361.     CrossRef
  • Advances in Hereditary Colorectal and Pancreatic Cancers
    Meghan L. Underhill, Katharine A. Germansky, Matthew B. Yurgelun
    Clinical Therapeutics.2016;[Epub]     CrossRef
  • 14,401 View
  • 88 Download
  • 4 Web of Science
  • 5 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP